20世纪的后15年,急性冠状动脉综合征治疗领域的两大进展就是急性心肌梗死的溶栓治疗和直接PTCA。它们与阿司匹林、β阻滞剂、血管紧张素转换酶抑制剂共同开创了急性心肌梗死的再灌注治疗时代。每年数以万计患者的生命得以挽救。然而,尽管有了抗血小板、抗凝和他汀类等稳定斑块的强有力的药物,无ST段抬高的急性冠状动脉综合征(ACS)的治疗仍未获得突破性 Two decades after the 20th century, two major advances in the treatment of acute coronary syndromes were thrombolytic therapy and direct PTCA in acute myocardial infarction. Together with aspirin, beta blockers and angiotensin-converting enzyme inhibitors, they have opened the era of reperfusion therapy for acute myocardial infarction. Tens of thousands of lives are saved each year. However, despite the powerful drugs against stable plaques such as platelets, anticoagulants and statins, breakthroughs have been made in the treatment of ST-elevation acute coronary syndromes (ACS)